Hacking goes squishy
By The Economist,
The Economist
| 09. 03. 2009
MANY of the world’s great innovators started out as hackers—people who like to tinker with technology—and some of the largest technology companies started in garages. Thomas Edison built General Electric on the foundation of an improved way to transmit messages down telegraph wires, which he cooked up himself. Hewlett-Packard was founded in a garage in California (now a national landmark), as was Google, many years later. And, in addition to computer hardware and software, garage hackers and home-build enthusiasts are now merrily cooking up electric cars, drone aircraft and rockets. But what about biology? Might biohacking—tinkering with the DNA of existing organisms to create new ones—lead to innovations of a biological nature?
The potential is certainly there. The cost of sequencing DNA has fallen from about $1 per base pair in the mid-1990s to a tenth of a cent today, and the cost of synthesising the molecule has also fallen. Rob Carlson, the founder of a firm called Biodesic, started tracking the price of synthesis a decade ago. He found a remarkably steady decline, from over $10 per base pair...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
